Alpha Fusion Accelerates Astatine-based Drug Discovery With Series B Funding
Alpha Fusion Accelerates Astatine-based Drug Discovery With Series B Funding
In the past year, several major pharmaceutical companies in OSAKA, Japan, Oct. 9, 2024 /PRNewswire/ -- Alpha Fusion, Inc. (CEO: Sunao Fujioka, headquartered in Kita-ku, Osaka), has raised a total of ¥1.02 billion through a Series B funding round. The round was led by SBI Investment Co., Ltd. and OSAKA University Venture Capital, with participation from several new investors. This funding will enable Alpha Fusion to accelerate its research and development efforts, enhance its supply chain, and deliver Japan's cutting-edge cancer therapies to the global market as quickly as possible.
日本大阪，2024年10月9日 /PRNewswire/ — Alpha Fusion, Inc.（首席执行官：藤冈须直总部位于大阪市北区）已通过b轮融资共筹集了10.2日元的资金。本轮融资由SBI投资有限公司和大阪大学风险投资公司牵头，有几位新投资者参与。这笔资金将使Alpha Fusion能够加快研发工作，增强其供应链，并尽快向全球市场提供日本尖端的癌症疗法。
Alpha Fusion Leading the World in Astatine-based Drug Discovery
Alpha Fusion 在基于阿斯他汀的药物发现方面处于世界领先地位
Alpha Fusion is a pioneering startup dedicated to bringing "Targeted Alpha Therapy (TAT) using Astatine (At-211)" to cancer patients worldwide. As a leader in the clinical development of Astatine-based therapeutics, Alpha Fusion is advancing its pipeline and building a highly efficient supply chain using cyclotrons in collaboration with partners across the globe. TAT is highly anticipated to become a foundational drug discovery platform in oncology, offering the potential to create numerous novel treatments.
Alpha Fusion是一家开创性的初创公司，致力于为全球癌症患者提供 “使用阿司他汀（At-211）的靶向阿尔法疗法（TAT）”。作为基于阿司他汀的疗法临床开发的领导者，Alpha Fusion正在推进其产品线，并与全球合作伙伴合作，使用回旋加速器建立高效的供应链。人们寄予厚望，TaT将成为肿瘤学领域的基础药物发现平台，为创造许多新疗法提供潜力。
In the past year, several major pharmaceutical companies in Europe and the U.S. have acquired startups developing Actinium (Ac-225) -based radiopharmaceuticals, signaling a surge of interest in this field. Astatine (At-211) is garnering attention for its short half-life, which anticipates clinical safety, its halogen properties that allow it to be directly labeled into low-mid sized-molecule ligands, its ease of sourcing raw material, and the simplicity of its production using cyclotrons.
在过去的一年中，欧洲和美国的几家主要制药公司收购了开发基于Actinium（Ac-225）的放射性药物的初创公司，这表明人们对该领域的兴趣激增。Astatine（At-211）因其短的半衰期而备受关注，这预示了临床安全性，其卤素特性使其可以直接标记为中低分子配体，易于采购原料，使用回旋加速器易于生产。
Business Progress and the Impact of Series B Funding
业务进展和b轮融资的影响
Since our Series A funding round in May 2023, Alpha Fusion has made significant strides, as detailed below:
自2023年5月我们的A轮融资以来，Alpha Fusion取得了长足的进步，详情如下：
1.1st Pipeline (Thyroid Cancer, Phase 1 ongoing): Progress in high-dose administration, approaching the determination of recommended dosages.
1.1号管道（甲状腺癌，第一阶段正在进行中）：大剂量给药的进展，接近推荐剂量的确定。
2. 2nd Pipeline (Prostate Cancer, Phase 1 ongoing): Successful completion of the world's first administration of [211At]PSMA-5 to a patient in June.
2. 第二条管道（前列腺癌，第 1 阶段正在进行中）：6 月成功完成了世界上首次向患者注射 [211At] PSMA-5 的药物。
3. Additional Pipelines: Multiple pipeline developments underway through both in-house R&D and collaborations.
3.其他管道：通过内部研发和合作，正在开发多条管道。
- July 2023: Initiated joint research with QST Chiba for tumor-specific targeting.
- August 2023: Began joint research with QST Takasaki/Niigata University on novel Astatine-labeling platform technologies.
- 2023 年 7 月：与 qSt Chiba 启动了针对肿瘤特异性靶向的联合研究。
- 2023 年 8 月：开始与 QsT 高崎/新泻大学联合研究新型 Astatine 标签平台技术。
4. Supply Chain: Progress in manufacturing preparations for clinical trial drugs both domestically and internationally, shaping the future of our supply chain.
4。供应链：国内外临床试验药物的生产准备工作取得进展，塑造了我们供应链的未来。
- First half of 2024: Completion of Osaka University's TAT Cyclotron building to enable efficient Astatine production.
- First half of 2024: Set up GMP facilities for clinical trial drug production in Japan and advanced collaboration with overseas CDMOs.
- 2024年上半年：大阪大学的TaT回旋加速器大楼竣工，以实现阿司他汀的高效生产。
- 2024年上半年：在日本建立用于临床试验药物生产的GMP设施，并推进与海外CDMO的合作。
5. Intellectual Property: Received patent approvals covering manufacturing methods, materials, and applications related to our pipeline.
5。知识产权：已获得专利批准，涵盖与我们的管道相关的制造方法、材料和应用。
6. Research Centers: Expanded domestic research operations, including a new center in Tsukuba (SakuLab-Tsukuba), in addition to Osaka University's research hub.
6。研究中心：扩大了国内研究业务，包括在筑波（Sakulab-Tsukuba）新建一个中心，以及大阪大学的研究中心。
7. Team Expansion: Strengthened the advisory board and enhanced functional capabilities critical to pharmaceutical development (e.g., supply chain, CMC, quality assurance, clinical development, regulatory affairs).
7。团队扩张：加强顾问委员会，增强对药物开发至关重要的职能能力（例如供应链、CMC、质量保证、临床开发、监管事务）。
With this funding, we will accelerate our R&D efforts and prepare for company-sponsored clinical trials, enhance our supply chain for GMP-grade clinical trial drug production domestically and internationally, and further expand our team. We are committed to demonstrating the unique advantages of Astatine-based drug discovery with tangible business results and clinical evidence.
有了这笔资金，我们将加快研发工作，为公司赞助的临床试验做准备，加强我们在国内和国际上生产GMP级临床试验药物的供应链，并进一步扩大我们的团队。我们致力于通过切实的业务成果和临床证据，展示基于阿司他汀的药物发现的独特优势。
Investors in Series B Round (in no particular order):
b轮投资者（排名不分先后）：
New Investors:
新投资者：
- SBI Investment Co., Ltd.
- Mitsui Mining & Smelting Co., Ltd.
- Kobe University Capital
- Joyo Capital Partners
- SBI 投资有限公司
- 三井矿业冶炼有限公司
- 神户大学之都
- Joyo 资本合伙人
Existing Investors (Follow-on Investment):
现有投资者（后续投资）：
- OSAKA University Venture Capital
- D3 LLC
- JGC Corporation
- 大阪大学风险投资
- D3 有限责任公司
- JGC 公司
Comments from Alpha Fusion CEO, Sunao Fujioka
Alpha Fusion首席执行官藤冈须直的评论
"In the past year, Alpha Fusion has made great progress. We are strategically advancing pipeline R&D and supply chain construction by leveraging the unique characteristics of Astatine: its short half-life, the potential for pipeline expansion due to its halogen properties, and the stable supply enabled by cyclotron production. The market is moving rapidly, with ongoing M&A and large-scale funding in the TAT sector globally. As we continue developing TAT pipelines, this funding round serves as a critical step toward company-sponsored clinical trials and GMP-grade Astatine drug production. We will push forward, engaging more stakeholders to realize our mission of advancing cancer treatment."
“在过去的一年中，Alpha Fusion取得了长足的进步。我们正在利用Astatine的独特特性来战略性地推进管道研发和供应链建设：其半衰期短，由于其卤素特性而有可能扩张管道，以及回旋加速器生产所带来的稳定供应。市场发展迅速，全球TaT领域正在进行并购和大规模融资。随着我们继续开发TaT管道，本轮融资是朝着公司赞助的临床试验和GMP级Astatine药物生产迈出的关键一步。我们将向前推进，让更多的利益相关者参与进来，以实现我们推进癌症治疗的使命。”
About Alpha Fusion
关于阿尔法融合
Alpha Fusion, Inc. was established to commercialize Astatine (At-211) drug discovery, based on research outcomes from Osaka University and the Japan Science and Technology Agency (JST) OPERA QiSS program. The company is dedicated to unleashing the therapeutic potential of Alpha (Astatine) therapy in the fast-emerging field of Targeted Alpha Therapy. Through world-class R&D and business development, Alpha Fusion aims to bring this innovative modality to the forefront of cancer treatment.
Alpha Fusion, Inc.成立的目的是根据大阪大学和日本科学技术厅（JST）OPERA QiS计划的研究成果，将Astatine（At-211）药物发现商业化。该公司致力于在快速崛起的靶向阿尔法疗法领域释放Alpha（Astatine）疗法的治疗潜力。通过世界一流的研发和业务发展，Alpha Fusion旨在将这种创新模式带到癌症治疗的最前沿。
Contact Information For further inquiries, please contact:
Email: [email protected]
联系信息如需进一步查询，请联系：
电子邮件：[电子邮件保护]
SOURCE Alpha Fusion Inc
来源 Alpha Fusion 公司
